| Neurogenetic and Muscular Disorders Research | Lifetime | 11 | AU 1 | 99.72 |
| Amyotrophic Lateral Sclerosis Research | Lifetime | 17 | AU 1 | 99.66 |
| Neuroscience and Neural Engineering | Lifetime | 142 | AU 5 | 99.23 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 157 | AU 4 | 99.45 |
| Peripheral Nerve Disorders | Lifetime | 58 | AU 1 | 98.74 |
| Peripheral Neuropathies and Disorders | Lifetime | 92 | AU 2 | 99.10 |
| Transcranial Magnetic Stimulation Studies | Lifetime | 102 | AU 9 | 98.86 |
| Cancer Treatment and Pharmacology | Lifetime | 346 | AU 5 | 98.99 |
| Genetic Neurodegenerative Diseases | Lifetime | 237 | AU 6 | 98.54 |
| Muscle activation and electromyography studies | Lifetime | 338 | AU 23 | 98.54 |
| Hereditary Neurological Disorders | Lifetime | 119 | AU 7 | 97.63 |
| Chemotherapy-related skin toxicity | Lifetime | 83 | AU 3 | 96.61 |
| Myasthenia Gravis and Thymoma | Lifetime | 206 | AU 2 | 97.02 |
| Neurological diseases and metabolism | Lifetime | 195 | AU 8 | 97.42 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 581 | AU 14 | 97.64 |
| Alzheimer's disease research and treatments | Lifetime | 972 | AU 33 | 97.64 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 493 | AU 15 | 96.55 |
| Multiple Myeloma Research and Treatments | Lifetime | 705 | AU 13 | 96.62 |
| Botulinum Toxin and Related Neurological Disorders | Lifetime | 937 | AU 30 | 95.63 |
| Neurological and metabolic disorders | Lifetime | 348 | AU 15 | 93.67 |
| Spinal Cord Injury Research | Lifetime | 670 | AU 28 | 94.03 |
| Restless Legs Syndrome Research | Lifetime | 359 | AU 5 | 91.43 |
| Autoimmune Neurological Disorders and Treatments | Lifetime | 607 | AU 19 | 87.40 |
| Neurology and Historical Studies | Lifetime | 644 | AU 31 | 81.78 |
| History of Medical Practice | Lifetime | 940 | AU 38 | 67.19 |
| Amyotrophic Lateral Sclerosis Research | 2021-2025 | 4 | AU 1 | 99.57 |
| Neurogenetic and Muscular Disorders Research | 2021-2025 | 15 | AU 1 | 99.27 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 225 | AU 5 | 97.05 |
| Neurological diseases and metabolism | 2021-2025 | 108 | AU 3 | 89.46 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 449 | AU 19 | 87.78 |
| Hereditary Neurological Disorders | 2021-2025 | 138 | AU 4 | 86.81 |
| Cancer Treatment and Pharmacology | 2021-2025 | 761 | AU 21 | 86.71 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 381 | AU 1 | 83.64 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 523 | AU 13 | 87.11 |
| Chemotherapy-related skin toxicity | 2021-2025 | 76 | AU 8 | 82.70 |
| Peripheral Nerve Disorders | 2021-2025 | 244 | AU 4 | 82.63 |
| Prion Diseases and Protein Misfolding | 2021-2025 | 210 | AU 4 | 80.55 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 474 | AU 3 | 77.62 |
